Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline

Core Viewpoint - JP Morgan upgraded Ionis Pharmaceuticals from neutral to overweight, highlighting potential label expansion for Tryngolza and promising candidates in its pipeline [2] Company Summary - The price target for Ionis Pharmaceuticals was raised from $49 to $80, indicating a potential upside of approximately 16% based on the closing price on October 7 [2]